Results 171 to 180 of about 487,593 (190)

Severe-acute-respiratory-syndrome-coronavirus-2-mRNA-vaccine

Reactions Weekly
  +9 more sources

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: An International Cardio‐Oncology Society (ICOS) statement

Ca-A Cancer Journal for Clinicians, 2020
Daniel J Lenihan, Joseph Carver, Charles Porter   +2 more
exaly  

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Guan-Hua Du, Jianping Zhao, Yang Jin
exaly  

Severe Covid-19

New England Journal of Medicine, 2020
David A Berlin, Roy M Gulick
exaly  

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Lancet, The, 2021
Noam Barda, Noa Dagan, Cyrille J Cohen
exaly  

Risk factors, pathophysiology, and treatment of hot flashes in cancer

Ca-A Cancer Journal for Clinicians, 2013
Gary R Elkins, Debra S Burns, Menggang Yu   +2 more
exaly  

Variant surface antigens of Plasmodium falciparum and their roles in severe malaria

Nature Reviews Microbiology, 2017
Mats Wahlgren, Suchi Goel, Reetesh Akhouri   +2 more
exaly  

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Lancet, The, 2009
Giles Peek, Ravindranath Tiruvoipati
exaly  

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

Lancet, The, 2005
Arjen M Dondorp, François H Nosten
exaly  

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

Lancet, The, 2010
Arjen M Dondorp, Caterina I Fanello, Rasaq Olaosebikan   +2 more
exaly